Navigation Links
No cell walls, no new cancer cells

Cancer cells, like houses, need building materials for their walls. And as with a house, the cell wall needs to be built at just the right moment to protect and allow the construction of internal components. A team from the Uppsala Branch of the global Ludwig Institute for Cancer Research (LICR) has not only shown how the cell gets this timing right, but has also conducted proof-of-principle studies that indicate taking away the cell's bricks and mortar is a potential strategy for cancer control.

"New cells are created by the duplication of existing cells through a highly-organized process known as the cell cycle," explains lead author, Dr. Maite Bengoechea Alonso. "Last year we discovered that a protein called SREBP1 that regulates the synthesis of lipids needed for new cell walls was regulated during the cell cycle. Now we show that the SREBP1 protein actually controls the cell cycle."

Senior author, LICR's Dr. Johan Ericsson, realized that disrupting the function of SREBP1 might prevent the lipid synthesis required for new cell walls. "In fact, we literally stopped the cell cycle in its tracks by removing SREBP1 from cells. It seems that if you don't have SREBP1 activity, you can't make lipids, and if you don't have lipids, you can't make new cells."

According to Dr. Ericsson, who is also a Research Fellow of the Royal Swedish Academy of Sciences, this approach might one day form the basis of a new strategy for the long-term control of cancer. "Cancer cells divide uncontrollably, so their need for lipids is more urgent and continuous than normal cells. Treatment with an inhibitor of SREBP1 might reduce the rate of cancer cell proliferation to slow down tumor growth, or might enhance the effect of targeted therapies that aim to actually kill cancer cells."


'"/>

Source:Ludwig Institute for Cancer Research


Page: 1

Related biology news :

1. Viral DNA sequence a possible trigger for breast cancer
2. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
3. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
4. Columbia research lifts major hurdle to gene therapy for cancer
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Mitochondrial DNA mutations play significant role in prostate cancer
7. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
8. BRCA1 causes ovarian cancer through indirect, biochemical route
9. Researchers identify target for cancer drugs
10. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
11. First atlas of key brain genes could speed research on cancer, neurological diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/17/2016)... 17, 2016  AIC announces that it has just released a new white paper ... high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or HPC ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. , ... Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based company ... System Integrator Partner certification gives customers confidence that our engineers are fully trained ...
(Date:12/7/2016)... EDMONTON , Dec. 7, 2016 /PRNewswire/ - ... the development and commercialization of immunotherapeutic products for ... has entered into an Antibody Manufacturing Development Program ... , USA) for its oregovomab antibody product. ... its Phase IIb clinical study in ovarian cancer ...
(Date:12/7/2016)... Ontario , Dec. 7, 2016  Nordion, ... with General Atomics (GA), welcome today,s award by ... Nuclear Security Administration (NNSA) of the Phase II ... project with Nordion and the University of Missouri ... II funding will support the establishment of a ...
(Date:12/7/2016)... The report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication Process (Extrusion, Injection Molding), ... 2026", published by MarketsandMarkets, the global market size was USD 645.4 Million in ... of CAGR of 6.2% between 2016 and 2026. ... ... , , ...
Breaking Biology Technology: